Professor of Diabetic Medicine and Health Policy
- Director of Diabetes Trials Unit
Amanda Ingham Adler trained in economics, medicine, and epidemiology in the US, and pharmacovigilance and pharmacoepidemiology in the UK. She directs the Diabetes Trial Unit, DTU, which oversees and collaborates on studies to address interventions related to diabetes and endocrinology to improve health; the Unit works closely with Health Economic Research Centre in Oxford and with other research groups around the UK and internationally.
In 1997, she joined the Diabetes Research Laboratory, Oxford, as the epidemiologist for the United Kingdom Prospective Diabetes Study (UKPDS). From 2004, she was appointed as NHS consultant physician at Addenbrooke’s Hospital, Cambridge. From 2009 until 2021, she chaired a Technology Appraisal Committee at the National Institute for Health and Care Excellence (NICE) evaluating drugs and devices across disease areas and making decisions to guide policy. With NICE, she also chaired the committee for new models to evaluate and purchase antimicrobials in the setting of antimicrobial resistance, the Clinical Guidelines for Newer Agents for Type 2 Diabetes, and the first Quality Standard for Diabetes. She received an award for Distinguished Contribution to NICE at the Parliamentary ceremony celebrating NICE’s 20th anniversary.
She chairs the World Health Organisation Technical Advisory Group for Diabetes. She sees patients in the NHS, and is an honorary consultant within the Oxford Centre for Diabetes Endocrinology and Metabolism. She is a Fellow of the Royal College of Physicians (London) and the Royal Statistical Society. She is on the Commission on Human Medicines (CHM) which advises ministers on the safety, efficacy and quality of medicinal products, and chairs the CHM’s Expert Advisory Group Cardiovascular, Diabetes, Renal, Respiratory and Allergy; she previously chaired the Medicines and Health Products Regulatory Agency’s (MHRA) Expert Group on the Safety of Insulin. She serves on the National Diabetes Audit Partnership Board and a commissioned funding committee of the National Institute of Health and Care Research (NIHR). She supports projects that set priorities under universal health coverage and led by the World Bank, NICE, the International Decision Support Initiative, and the Organisation for Economic Co-operation and Development.
Calibrating a network meta-analysis of diabetes trials of sodium glucose cotransporter 2 inhibitors, glucagon-like peptide-1 receptor analogues and dipeptidyl peptidase-4 inhibitors to a representative routine population: a systematic review protocol.
Butterly E. et al, (2022), BMJ Open, 12
Endpoints and estimands: understanding trials of weight-loss drugs.
Adler AI., (2022), Nat Med, 28, 2005 - 2006
How can we optimise health technology assessment and reimbursement decisions to accelerate access to new cardiovascular medicines?
Cowie MR. et al, (2022), International journal of cardiology, 365, 61 - 68
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
Nazarzadeh M. et al, (2022), Lancet Diabetes Endocrinol, 10, 645 - 654
Ethnic and socioeconomic disparities in initiation of second-line antidiabetic treatment for people with type 2 diabetes in England: A cross-sectional study.
Bidulka P. et al, (2022), Diabetes, obesity & metabolism